The closing price of Beam Therapeutics Inc. (NASDAQ: BEAM) was $34.51 for the day, down -1.82% from the previous closing price of $35.15. In other words, the price has decreased by -$0.64 from its previous closing price. On the day, 1083049 shares were traded. BEAM stock price reached its highest trading level at $35.59 during the session, while it also had its lowest trading level at $34.03.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Our analysis of BEAM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.90 and its Current Ratio is at 4.90. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 04 when Simon Amy sold 11,654 shares for $29.70 per share. The transaction valued at 346,115 led to the insider holds 69,308 shares of the business.
Evans John M. sold 6,493 shares of BEAM for $188,904 on Apr 04. The CEO now owns 1,117,979 shares after completing the transaction at $29.09 per share. On Apr 04, another insider, Burrell Terry-Ann, who serves as the Chief Financial Officer of the company, sold 2,186 shares for $29.09 each. As a result, the insider received 63,598 and left with 47,117 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BEAM now has a Market Capitalization of 2.49B and an Enterprise Value of 1.59B. For the stock, the TTM Price-to-Sale (P/S) ratio is 34.64 while its Price-to-Book (P/B) ratio in mrq is 3.27. Its current Enterprise Value per Revenue stands at 20.73 whereas that against EBITDA is -4.60.
Stock Price History:
Over the past 52 weeks, BEAM has reached a high of $73.27, while it has fallen to a 52-week low of $28.04. The 50-Day Moving Average of the stock is 32.05, while the 200-Day Moving Average is calculated to be 43.07.
BEAM traded an average of 980.26K shares per day over the past three months and 1.06M shares per day over the past ten days. A total of 72.27M shares are outstanding, with a floating share count of 69.16M. Insiders hold about 1.50% of the company’s shares, while institutions hold 87.10% stake in the company. Shares short for BEAM as of Apr 27, 2023 were 12.73M with a Short Ratio of 12.73M, compared to 13.61M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 17.05% and a Short% of Float of 22.16%.
The firm’s stock currently is rated by 13 analysts. On average, analysts expect EPS of -$1.42 for the current quarter, with a high estimate of -$1.15 and a low estimate of -$1.73, while EPS last year was -$1.02. The consensus estimate for the next quarter is -$1.43, with high estimates of -$1.15 and low estimates of -$1.81.
Analysts are recommending an EPS of between -$4.69 and -$6.74 for the fiscal current year, implying an average EPS of -$5.63. EPS for the following year is -$5.93, with 15 analysts recommending between -$4.36 and -$7.81.
It is expected that $90B in revenue will be generated in the current quarter, according to 10 analysts. It ranges from a high estimate of $25M to a low estimate of $5M. As of the current estimate, Beam Therapeutics Inc.’s year-ago sales were $16.65M, an estimated increase of 8.40% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $18.05M, an increase of 127.30% over than the figure of $8.40% in the same quarter last year. There is a high estimate of $25M for the next quarter, whereas the lowest estimate is $5M.
A total of 14 analysts have provided revenue estimates for BEAM’s current fiscal year. The highest revenue estimate was $99.2M, while the lowest revenue estimate was $24M, resulting in an average revenue estimate of $74.01M. In the same quarter a year ago, actual revenue was $60.92M, up 21.50% from the average estimate.